WASHINGTON--Perspectum awarded new FDA research grant to evaluate biomarker for use in rare disease treatment.

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

The market for multiplex biomarker imaging is anticipated to reach a valuation of USD 1,631.4 million by 2034, up from USD ...

“We need future studies to help us understand the relationship between cholesterol variability and dementia risk,” she said ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

The biomarker human neutrophil lipocalin HNL was previously shown to be a useful indicator of bacterial infections. Now, the ...

Investors included Techstars, Jinqiu Capital, MiraclePlus, Hat-trick... at 12:20 Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development Perspectum, a leader in ...

Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS ...

Breast Cancer Awareness Month brings attention to important advancements in cancer care, and today, we're partnering with ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

The rapid evolution in personalized healthcare has driven the development of wearable biomedical devices, with microneedle ...